Stay updated with breaking news from Ccdi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings revealed more than 5,000 excess deaths from CDI and 35.6% excess risk compared to the expected number of disease deaths calculated using data from the National Vital Statistics System.
Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.
Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.
Patients with CDI and COVID-19 faced a higher risk of mortality and had higher CCI scores, a longer length of stay, and greater total hospital costs than patients infected with COVID-19 but not CDI.
Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.